C07K 2319/04
Containing an er retention signal such as a c-terminal hdel motif
Official title: containing an ER retention signal such as a C-terminal HDEL motif
C07K2319/04 (Containing an er retention signal such as a c-terminal hdel motif) appears on 168 US grants and 246 published applications in this corpus.
Search patents in C07K- Granted patents
- 168
- Published applications
- 246
- Assignees
- 143
- Inventors
- 420
- Latest grant
- 26 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1990 | 1 | 0 |
| 1991 | 0 | 0 |
| 1992 | 2 | 0 |
| 1993 | 1 | 0 |
| 1994 | 2 | 0 |
| 1995 | 1 | 0 |
| 1996 | 5 | 0 |
| 1997 | 1 | 0 |
| 1998 | 4 | 0 |
| 1999 | 4 | 0 |
| 2000 | 3 | 0 |
| 2001 | 4 | 0 |
| 2002 | 4 | 8 |
| 2003 | 5 | 10 |
| 2004 | 3 | 8 |
| 2005 | 2 | 9 |
| 2006 | 5 | 12 |
| 2007 | 1 | 6 |
| 2008 | 6 | 9 |
| 2009 | 4 | 6 |
| 2010 | 1 | 7 |
| 2011 | 5 | 8 |
| 2012 | 8 | 7 |
| 2013 | 2 | 8 |
| 2014 | 9 | 9 |
| 2015 | 6 | 9 |
| 2016 | 9 | 16 |
| 2017 | 13 | 14 |
| 2018 | 9 | 16 |
| 2019 | 4 | 13 |
| 2020 | 7 | 9 |
| 2021 | 5 | 8 |
| 2022 | 9 | 16 |
| 2023 | 6 | 7 |
| 2024 | 7 | 16 |
| 2025 | 8 | 10 |
| 2026 | 2 | 5 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- De-immunized Shiga toxin a subunit effector polypeptides for applications in mammals26 May 2026US 12,637,495 B2Molecular Templates, Inc.
- Recombinant erIL-15 NK cells6 Jan 2026US 12,516,093 B2ImmunityBio, Inc.
- Engineered cytolytic immunecell9 Dec 2025US 12,492,410 B2Autolus Limited
- T cell receptor-deficient chimeric antigen receptor T-cells and methods of use thereof25 Nov 2025US 12,479,914 B2National University of Singapore
- Porcine epidemic diarrhea (PED) virus vaccine composition and preparation method thereof15 Jul 2025US 12,357,686 B2Bioapplications Inc.
- Nucleic acid vaccine for activating nkg2c+ natural killer cells24 Sep 2026US 2026/0286356 A1Charite-Universitatsmedizin Berlin
- Recombinant eril-15 nk cells7 May 2026US 2026/0125438 A1ImmunityBio, Inc.
- Treatment of epilepsy2 Apr 2026US 2026/0091135 A1Modulight Bio Ltd.
- Cell membrane penetrating conjugates for gene editing5 Mar 2026US 2026/0062718 A1Cygenica Limited
- Linc complex inhibiting polypeptides1 Jan 2026US 2026/0001923 A1Agency for Science, Technology and Research
Most cited
By later US patents
- Hybrid immunoglobulins817US 5,116,964 AGenentech, Inc. · 1992
- Interleukin-1 receptors165US 4,968,607 AImmunex Corporation · 1990
- Methods for producing modified glycoproteins158US 7,029,872 B2GlycoFi, Inc. · 2006
- Soluble human interleukin-1 receptors, compositions and method of use109US 5,180,812 AImmunex Corporation · 1993
- Methods for producing modified glycoproteins84US 7,326,681 B2GlycoFi, Inc. · 2008